Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (671-680 of 713) with videos related to

Pageof 72
Sort By:
Lancet (London, England)|April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Journal of Medical Virology|September 7, 2023
Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workersPankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, et al.
Blood Advances|August 23, 2021
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosisNaveen Pemmaraju, Bing Z Carter, Prithviraj Bose, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 11, 2013
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?Mitchell Sabloff, Ronald M Sobecks, Kwang Woo Ahn, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2017
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeStefan O Ciurea, Mithun V Shah, Rima M Saliba, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Pageof 72

Showing results (671-680 of 713) with videos related to

Sort By:
Pageof 72
Lancet (London, England)|April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Journal of Medical Virology|September 7, 2023
Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workersPankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, et al.
Blood Advances|August 23, 2021
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosisNaveen Pemmaraju, Bing Z Carter, Prithviraj Bose, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 11, 2013
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?Mitchell Sabloff, Ronald M Sobecks, Kwang Woo Ahn, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2017
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeStefan O Ciurea, Mithun V Shah, Rima M Saliba, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Pageof 72